Products Details

Product Description

– BC-11 hydrobromide is a selective TMPRSS2 inhibitor (TMPRSS2 is a key host cellular factor for viral entry and SARS-CoV-2 pathogenesis), and a selective urokinase (uPA) inhibitor (IC50=8.2 μM). BC-11 hydrobromide is cytotoxic to triple-negative MDA-MB231 breast cancer cells. BC-11 hydrobromide is used in research on viral infections and cancer[1][2][3].

Web ID

– HY-108447

Shipping

– Room temperature

Molecular Formula

– C8H12BBrN2O2S

References

– [1]Moumbock AFA, et al. BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry. Arch Pharm (Weinheim). 2023 Jan;356(1):e2200371.|[2]Semina E, et al. Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching. Eur J Cell Biol. 2016 Sep;95(9):295-310.|[3]Longo A, et al. Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells. Molecules. 2015 May 28;20(6):9879-89.

CAS Number

– 443776-49-6

Molecular Weight

– 290.97

SMILES

– NC(SCC1=CC=C(B(O)O)C=C1)=N.[H]Br

Clinical Information

– No Development Reported

Research Area

– Cancer; Infection

Solubility

– 10 mM in DMSO

Target

– PAI-1;SARS-CoV;Ser/Thr Protease

Pathway

– Anti-infection;Metabolic Enzyme/Protease

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=